Central Trust CO Neurocrine Biosciences Inc Transaction History
Central Trust CO
- $3.97 Billion
- Q1 2025
A detailed history of Central Trust CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Central Trust CO holds 76 shares of NBIX stock, worth $9,629. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76
Previous 86
11.63%
Holding current value
$9,629
Previous $11,000
27.27%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding NBIX
# of Institutions
649Shares Held
97.6MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.8 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.26 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$701 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$616 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$338 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...